In clinical trials1,2,3Evidence: Smaller human trialsBrain, nerves and sleep

Cibinetide1

Also called ARA 2901

Key takeaway

Cibinetide, also called ARA 290, is a synthetic 11-amino-acid peptide recorded in FDA’s substance registry.1 In a randomized, placebo-controlled Phase 2b trial of 64 people with sarcoidosis-related small nerve fiber loss and nerve pain, one of three strengths increased corneal nerve fiber area after 28 days.2 No FDA approval is reported in the sources reviewed here. Cibinetide does not appear on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.1,3,5

Cibinetide at a glance

What it isA synthetic 11-amino-acid peptide (pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser), recorded as cibinetide, ARA 290 and pHBSP in FDA’s substance registry.1
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list cibinetide.1,3
Human evidenceSmall randomized, placebo-controlled trials, including a 28-day Phase 2b trial in 64 people with sarcoidosis-related nerve damage.2
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is cibinetide?

Cibinetide is a synthetic peptide of 11 amino acids. FDA’s substance registry records it as cibinetide, ARA 290, ARA-290 and pHBSP.1

How is cibinetide thought to work?

The 2017 trial authors describe cibinetide as an agonist of the innate repair receptor and studied whether it could reverse the loss of small nerve fibers.2

What do human studies show?

In the 2017 Phase 2b trial, 64 people with sarcoidosis-associated small nerve fiber loss and neuropathic pain were randomized to one of three strengths of cibinetide or placebo for 28 days.2

The main outcome, change in corneal nerve fiber area, improved significantly only with the middle strength. Pain improved significantly in all groups; among those with moderate to severe pain, the placebo-corrected reduction with the middle strength was not statistically significant.2

What the evidence base contains

  • Controlled human trial A randomized, placebo-controlled Phase 2b trial in 64 people with sarcoidosis-associated small nerve fiber loss and neuropathic pain, lasting 28 days (2017).2

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is cibinetide FDA-approved?

None of the sources reviewed here reports an approval of cibinetide by FDA.1,3

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list cibinetide.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Cibinetide is not among them.4,5

Timeline

  1. A Phase 2b trial of cibinetide in 64 people with sarcoidosis-related nerve damage is published.2
  2. FDA’s compounding safety-risk page is last updated; it does not list cibinetide.3

What is still unknown?

Whether the nerve fiber changes seen over 28 days lead to lasting relief of pain or better function, which the trial was too short and small to show.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Cibinetide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Cibinetide are a bounded selection, not every registration or paper about Cibinetide. For the years before Cibinetide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Cibinetide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Cibinetide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not FDA-approved; studied in clinical trials. A randomized, placebo-controlled trial of 64 people found more corneal nerve fibers with one strength after 28 days. Cibinetide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Cibinetide?

Not FDA-approved; studied in clinical trials. A randomized, placebo-controlled trial of 64 people found more corneal nerve fibers with one strength after 28 days. Cibinetide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
3
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.↗Source date September 28, 2020
  2. Literature metadata · added November 16, 2026

    ARA 290 for treatment of small fiber neuropathy in sarcoidosis.↗Source date May 25, 2018
  3. Literature metadata · added November 16, 2026

    ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.↗Source date May 25, 2018

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Cibinetide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

4Selected dated records
9Connected citations
3Populated source years2017–2020
2/4Record lanes present

Registered human studies

Trial composition

1 of 1 selected trial records include at least one phase value; 1 of 1 include a status value in the retained structured contract.

PhasesPhase 2 1
Status at observationCompleted 1

PubMed bibliography

Publication composition

3 of 3 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 3Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
4

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 4 dated records

Research hub

Explore the Cibinetide evidence record

Open all 4 records →
4Dated records
2Evidence types
4Cited public sources
3Source years

Change ledger

Recently changed for Cibinetide

Open all 4 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT02039687

PeptideScanner retained ClinicalTrials.gov record NCT02039687 at 2026-11-16T01:46:13.488Z. Its registry update date was 2017-04-18, and PeptideScanner's reviewed identity mapping was cibinetide.

PeptideScanner change date
November 16, 2026
Cited source date
April 18, 2017
Evidence lane
Clinical trials
Record added

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

PubMed lists PMID 24555851 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2014-02-21 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
May 25, 2018
Evidence lane
Literature metadata
Record added

ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.

PubMed lists PMID 26774587 in Peptides as Journal Article, with publication-date metadata of 2016-01-13 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
May 25, 2018
Evidence lane
Literature metadata

Official-source collections

Source records for Cibinetide

Open the full research atlas →
PubMed3

3 with attributed title, venue, publication-date, and type metadata.

  1. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.Journal of clinical medicine · 2020 07 14
  2. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.Peptides · 2016 01 13
  3. ARA 290 for treatment of small fiber neuropathy in sarcoidosis.Expert opinion on investigational drugs · 2014 02 21
Explore all selected literature →

Evidence types

Coverage by source year

Selected records span April 18, 2017 to September 28, 2020. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,3
  • U.S. Department of Health and Human Services4
Dated updates connected to this profile · 4

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.↗

    PubMed lists PMID 32674280 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2020-07-14 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    ARA 290 for treatment of small fiber neuropathy in sarcoidosis.↗

    PubMed lists PMID 24555851 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2014-02-21 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.↗

    PubMed lists PMID 26774587 in Peptides as Journal Article, with publication-date metadata of 2016-01-13 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT02039687↗

    PeptideScanner retained ClinicalTrials.gov record NCT02039687 at 2026-11-16T01:46:13.488Z. Its registry update date was 2017-04-18, and PeptideScanner's reviewed identity mapping was cibinetide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Cibinetide (ARA 290) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (2017) · PMID 28475703 ↗

    Investigative Ophthalmology & Visual Science · Official source · Source checked November 15, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026